

Therapy & Guidelines Sub-Committee, British Association of Dermatologists

Comments on the appraisal consultation document and evaluation report relating to the use of golimumab for the treatment of psoriatic arthritis.

The Therapy & Guidelines and the Biologics Register Sub-committees of the British Association of Dermatologists have reviewed this draft ACD on the use of golimumab for the treatment of psoriatic arthritis. All of the relevant evidence appears to have been taken into account, and the summaries of the clinical and cost effectiveness of golimumab represent reasonable interpretation of the evidence. The provisional recommendations form an appropriate basis for guidance as to the use of golimumab in the NHS, and contain no discriminatory aspects.

There were no comments relating to the evaluation report, and no specific comments relating to the efficacy of golimumab in the treatment of the cutaneous manifestations of psoriasis.

Michael Tidman
Chair, T&G Sub-committee

29th October 2010